Viatris (VTRS) Liabilities from Discontinued Operations (2022 - 2024)
Viatris' (VTRS) quarterly Liabilities from Discontinued Operations came in at 32800000.0 in Q2 2024, down 86.03% quarter-over-quarter from 234800000.0 in Q1 2024.
Viatris (VTRS) Liabilities from Discontinued Operations (2022 - 2024) Analysis & Trends
Viatris' Liabilities from Discontinued Operations history runs 3 years deep, the most recent figure standing at 32800000.0 for Q2 2024.
- On a quarterly basis, Liabilities from Discontinued Operations changed N/A year-over-year to 32800000.0 in Q2 2024; TTM through Jun 2024 was 32800000.0, a N/A change from a year earlier, with the FY2023 full-year figure at 275100000.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations eased to 32800000.0 in Q2 2024 per VTRS's latest filing, from 234800000.0 in the prior quarter.
- Across five years, Liabilities from Discontinued Operations topped out at 335300000.0 in Q3 2022 and bottomed at 14300000.0 in Q3 2023.
- The 3-year median for Liabilities from Discontinued Operations is 275100000.0 (2023), against an average of 207871428.57.
- Biggest YoY gain for Liabilities from Discontinued Operations was 95.74% in 2023; the steepest drop was 95.74% in 2023.
- Year by year, Liabilities from Discontinued Operations stood at 335300000.0 in 2022, then fell by 17.95% to 275100000.0 in 2023, then tumbled by 88.08% to 32800000.0 in 2024.
- Per Business Quant, the three latest VTRS Liabilities from Discontinued Operations figures stand at 32800000.0 (Q2 2024), 234800000.0 (Q1 2024), and 275100000.0 (Q4 2023).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 32.80 Mn |
| Jun 30, 2024 | 32.80 Mn |
| Mar 31, 2024 | 234.80 Mn |
| Mar 31, 2024 | 234.80 Mn |
| Dec 31, 2023 | 275.10 Mn |
| Dec 31, 2023 | 275.10 Mn |
| Sep 30, 2023 | 14.30 Mn |
| Sep 30, 2023 | 14.30 Mn |
| Sep 30, 2022 | 335.30 Mn |
| Sep 30, 2022 | 335.30 Mn |
| Jun 30, 2022 | 285.10 Mn |
| Jun 30, 2022 | 285.10 Mn |
| Mar 31, 2022 | 277.70 Mn |
| Mar 31, 2022 | 277.70 Mn |